Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 230Breast Neoplasms 187Ovarian Neoplasms 113Neoplasms 100Neoplasm Metastasis 59Lung Neoplasms 54Fallopian Tube Neoplasms 47Triple Negative Breast Neoplasms 44Stomach Neoplasms 41Parkinson Disease 4, Autosomal Dominant Lewy Body 41Endometrial Neoplasms 37Carcinoma, Ovarian Epithelial 32Squamous Cell Carcinoma of Head and Neck 28Uterine Cervical Neoplasms 24Esophageal Neoplasms 21Carcinoma 21Colorectal Neoplasms 20Recurrence 19Melanoma 18Esophageal Squamous Cell Carcinoma 18Small Cell Lung Carcinoma 16Pancreatic Neoplasms 16Head and Neck Neoplasms 14Solid Tumors 12Adenocarcinoma 12Advanced Solid Tumors 11Carcinoma, Renal Cell 10Carcinoma, Squamous Cell 9Urinary Bladder Neoplasms 8Solid Tumor 8

Interventions

Trastuzumab 1Paclitaxel 1MM-111 1Lapatinib 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × HER-2 Gene Amplification × Paclitaxel × Clear all
NCT01304784 2015-12-16

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
100 enrolled

HER-2 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡